Last reviewed · How we verify
Inclusion conjunctivitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Doxycyclin · Bulovka Hospital
- Abelcet · Astellas Pharma
- Demethylchlortetracycline · Pfizer
- Meclan · Johnson And Johnson
- Minocycline Hydrochloride · Rempex
MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death. - Vibramycin · Generic (originally Pfizer)
- Minocyclin · University of Southern California
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Inclusion conjunctivitis patent landscape — cliff calendar, originator estates, attackable patents
- Inclusion conjunctivitis treatment landscape brief
- Inclusion conjunctivitis treatment updates RSS
Frequently asked questions about Inclusion conjunctivitis
What drugs treat Inclusion conjunctivitis?
Tracked treatments include Ramycin, Doxycyclin, Abelcet, Demethylchlortetracycline, Meclan, Minocycline Hydrochloride, Vibramycin, Minocyclin.
What is the treatment for Inclusion conjunctivitis?
Standard treatment for Inclusion conjunctivitis includes Ramycin, Doxycyclin, Abelcet, Demethylchlortetracycline, Meclan. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Inclusion conjunctivitis patent cliff · Inclusion conjunctivitis CI report
- Treatment: Ramycin
- Treatment: Doxycyclin · Bulovka Hospital
- Treatment: Abelcet · Astellas Pharma
- Treatment: Demethylchlortetracycline · Pfizer
- Treatment: Meclan · Johnson And Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing